PXMD

8-K - PaxMedica, Inc. (0001811623) (Filer)

BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been a

SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

EFFECT - PaxMedica, Inc. (0001811623) (Filer)

S-1 - PaxMedica, Inc. (0001811623) (Filer)

10-Q - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275416). The offering is expected to close on or about

Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC:PINKPXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense st

NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

8-K - PaxMedica, Inc. (0001811623) (Filer)

TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the "Company" or "PaxMedica") (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance

10-Q - PaxMedica, Inc. (0001811623) (Filer)

TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders. Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for  anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)." The com

8-K - PaxMedica, Inc. (0001811623) (Filer)

LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, takes center stage in the episode. During this insightful conversation, Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, joined host Stuart Smith to di

8-K - PaxMedica, Inc. (0001811623) (Filer)

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (NASDAQ:PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company's recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region. How

Gainers Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards by 16.62% to $0.57. The market value of their outstanding shares is at $6.2 million. Portage Biotech (NASDAQ:PRTG) shares moved upwards by 14.83% to $0.28. The company's market cap stands at $5.4 million. Erasca (NASDAQ:ERAS) stock rose 13.73% to $2.04. The company's market cap stands at $308.4 million. MSP Recovery (NASDAQ:LIFW) shares moved upwards by 13.25% to $0.94. The company's market cap stands at $14.9 million. As per the press release, Q4 earnings came out 4 days ago. Cue Health